Visser SAG - Search Results

1

Assessment of translational risk in drug research: Role of biomarker classification and mechanism-based PKPD concepts.

Visser SAG, Bueters TJH. Visser SAG, et al. Eur J Pharm Sci. 2017 Nov 15;109S:S72-S77. doi: 10.1016/j.ejps.2017.08.006. Epub 2017 Aug 13. Eur J Pharm Sci. 2017. PMID: 28811131 Review.

2

Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery.

Bueters T, Gibson C, Visser SA. Bueters T, et al. Future Med Chem. 2015;7(17):2351-69. doi: 10.4155/fmc.15.143. Epub 2015 Nov 24. Future Med Chem. 2015. PMID: 26599348 Review.

3

The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives.

Bueters T, Ploeger BA, Visser SA. Bueters T, et al. Drug Discov Today. 2013 Sep;18(17-18):853-62. doi: 10.1016/j.drudis.2013.05.001. Epub 2013 May 9. Drug Discov Today. 2013. PMID: 23665277 Review.

4

Correct assessment of new compounds using in vivo screening models can reduce false positives.

Bueters TJ, Hoogstraate J, Visser SA. Bueters TJ, et al. Drug Discov Today. 2009 Jan;14(1-2):89-94. doi: 10.1016/j.drudis.2008.09.003. Epub 2008 Oct 22. Drug Discov Today. 2009. PMID: 18840543 Review.

5

In vivo and ex vivo inhibition of spinal nerve ligation-induced ectopic activity by sodium channel blockers correlate to in vitro inhibition of NaV1.7 and clinical efficacy: a pharmacokinetic-pharmacodynamic translational approach.

Kalezic I, Luo L, Lund PE, Eriksson AB, Bueters T, Visser SA. Kalezic I, et al. Pharm Res. 2013 May;30(5):1409-22. doi: 10.1007/s11095-013-0979-6. Epub 2013 Feb 1. Pharm Res. 2013. PMID: 23371514

6

Model-based drug discovery: implementation and impact.

Visser SA, Aurell M, Jones RD, Schuck VJ, Egnell AC, Peters SA, Brynne L, Yates JW, Jansson-Löfmark R, Tan B, Cooke M, Barry ST, Hughes A, Bredberg U. Visser SA, et al. Drug Discov Today. 2013 Aug;18(15-16):764-75. doi: 10.1016/j.drudis.2013.05.012. Epub 2013 May 29. Drug Discov Today. 2013. PMID: 23726890 Review.

7

A PK-PD model-based assessment of sugammadex effects on coagulation parameters.

Bosch R, van Lierop MJ, de Kam PJ, Kruithof AC, Burggraaf J, de Greef R, Visser SA, Johnson-Levonas AO, Kleijn HJ. Bosch R, et al. Eur J Pharm Sci. 2016 Mar 10;84:9-17. doi: 10.1016/j.ejps.2015.12.028. Epub 2015 Dec 30. Eur J Pharm Sci. 2016. PMID: 26747019 Clinical Trial.

8

A Model-Informed Drug Discovery and Development Strategy for the Novel Glucose-Responsive Insulin MK-2640 Enabled Rapid Decision Making.

Visser SAG, Kandala B, Fancourt C, Krug AW, Cho CR. Visser SAG, et al. Clin Pharmacol Ther. 2020 Jun;107(6):1296-1311. doi: 10.1002/cpt.1729. Epub 2020 Feb 3. Clin Pharmacol Ther. 2020. PMID: 31889297 Free PMC article.

9

Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid.

Välitalo PA, Griffioen K, Rizk ML, Visser SA, Danhof M, Rao G, van der Graaf PH, van Hasselt JG. Välitalo PA, et al. Pharm Res. 2016 Apr;33(4):856-67. doi: 10.1007/s11095-015-1832-x. Epub 2015 Dec 1. Pharm Res. 2016. PMID: 26626793

10

Model-based evaluation of drug-induced QTc prolongation for compounds in early development.

Dubois VF, Yu H, Danhof M, Della Pasqua O; Cardiovascular Safety Project Team and TI Pharma PKPD Platform. Dubois VF, et al. Br J Clin Pharmacol. 2015 Jan;79(1):148-61. doi: 10.1111/bcp.12482. Br J Clin Pharmacol. 2015. PMID: 25099645 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82 results

Search Page

Filters